A phase II study of oxaliplatin/5-FU/Avastin and concurrent radiation to determine tolerability in patients with simultaneous primary and metastatic rectal cancer.

Trial Profile

A phase II study of oxaliplatin/5-FU/Avastin and concurrent radiation to determine tolerability in patients with simultaneous primary and metastatic rectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Rectal cancer
  • Focus Adverse reactions
  • Acronyms Chrome-B
  • Most Recent Events

    • 11 Oct 2016 Results of this study, presented at the 41st European Society for Medical Oncology Congress.
    • 08 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top